Stock Report

All about this stock under one free report Last Updated: 13-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Summit Therapeutics - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$17.55

up-down-arrow $0.55 (3.24%)

As on 11-Sep-2026 16:24EDT

Market cap

info icon

$14,044 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

17.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -- -- -10.72 -364.54 -292.17
Net Profit -13.87 6.94 -130.47 -344.22 -291.89
EPS -13.47 11.10 -122.88 5.70 -18.61
Book Value -- -- 51.47 19.29 -3.83
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info ----------
Net Margin info ----------
Return on equity info -----153.01-270.02-91.04
Return on Capital info -------263.03-70.68
Return on Assets info -----173.90-238.44-64.16
Debt to Equity (x) info ----0.000.030.02

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
-263.03
-70.68
-148.32
-121.99
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-153.01

Lower than Peers by 112.68

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
-153.01
-270.02
-91.04
-601.85
-512.79
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-173.90

Lower than Peers by 142.65

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
-173.90
-238.44
-64.16
-141.83
-116.97
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
--
--
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
--
--
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
-1.00
-1.00
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-10.72

Lower than Peers by 9.70

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
-10.72
-540.58
-142.11
-24.48
-32.26
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-130.47

Lower than Peers by 122.94

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
-130.47
-510.72
63.35
-726.73
-640.17
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-122.88

Lower than Peers by 137.11

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
-122.88
-4.88
0.65
--
-1.90
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

321.10

Higher than Peers by 331.24

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
321.10
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
0.03
0.02
1.37
1.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
0.01
0.01
0.01
0.04
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

6.96

Higher than Peers by 1.15

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
6.96
9.87
10.15
9.30
9.30
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

6.96

Higher than Peers by 1.26

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
6.96
--
--
9.18
9.15
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
-19.40
-5.45
-4.23
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
--
--
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
59.41
27,077.05
27,077.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
31,626.28
77.54
269.22
219.64
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Jan-24
Dec-23
Summit Therapeutics - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...